Episode

Episode 53. Belantamab Makes a Comeback with Dr. Hang Quach

Podcast
Blood Cancer Talks
Published
Nov 13, 2024
Duration seconds
2681
Processing state
not_requested
Canonical source
https://share.transistor.fm/s/5d7e0d35
Audio
https://media.transistor.fm/5d7e0d35/6a9783a7.mp3
JSON
/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-53-belantamab-makes-a-comeback-with-dr-hang-quach
Markdown
/podcast/blood-cancer-talks-5570002/episode-53-belantamab-makes-a-comeback-with-dr-hang-quach.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-53-belantamab-makes-a-comeback-with-dr-hang-quach/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-53-belantamab-makes-a-comeback-with-dr-hang-quach.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed: 1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828933/ 2. DREAMM-8 RCT: Belantamab-Pd vs PVd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828951/ 3. Long-term follow-up of CASSIOPEIA Trial: https://pubmed.ncbi.nlm.nih.gov/38889735/ 4. Update on MRD data from PERSEUS Trial: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7502